Background: Previous studies have investigated the association of X-Ray Repair Cross-Complementing Group 2 (XRCC2) rs3218536 polymorphism with breast and ovarian cancer. However, this association remains conflicting. Therefore, we have performed the current systematic review and meta-analysis to clarify the association between XRCC2 rs3218536 polymorphism with risk of breast and ovarian cancer. Methods: We conducted a search in PubMed, Google Scholar and ISI Web of Science to select relevant studies on the association of XRCC2 rs3218536 polymorphism with breast and ovarian cancer susceptibility. We calculated the odds ratios (OR) and 95% confidence intervals (CI) for five genetic contrasts. In addition, a stratified analysis was conducted cancer type, ethnicity and HWE status. Results: A total of 17 studies with 5694 cases and 6450 controls for breast cancer and nine case-control studies with 4464 cases and 6353 controls for ovarian cancer were identified for the analysis of the association with XRCC2 rs3218536 polymorphism. The pooled ORs revealed that XRCC2 rs3218536 polymorphism was associated with breast cancer under the heterozygote contrast (AG vs. GG: OR = 0.929, 95% CI = 0.873-0.987, p=0.018) and ovarian cancer under dominant contrast (AA+AG vs. GG: OR = 0.725, 95% CI = 0.537-0.979, p=0.036) in the overall population. The stratified analysis indicated a significant association of XRCC2 rs3218536 polymorphism with breast and ovarian cancer risk among Caucasians. Conclusion: Inconsistent with previous meta-analysis, this meta-analysis shows that the XRCC2 rs3218536 polymorphism was associated with breast and ovarian cancer risk in overall population, especially among Caucasians.
Introduction
Breast cancer is the most frequently diagnosed cancer among women, which contributed to 25 % of all cancer cases in women worldwide Yazdi et al., 2015) . A hereditary component accounts for 10-15% of all breast and ovarian cancer cases. It is estimated that 30% of hereditary breast cancer cases are due to mutations in one of the BRCA1 and BRCA2 genes (Forat-Yazdi et al., 2015; Neamatzadeh et al., 2015) . Ovarian cancer is the fifth leading cause of cancer deaths occurring in women and leading cause of mortality from gynecologic cancer (Stewart et al., 2013) . It is estimated that familial ovarian cancer accounts for 5-15% of the total cases of ovarian cancer (Lynch et al., 2009) . It is known that family history is one of the most important risk factors in ovarian cancer development. A possible genetic contribution to both breast and ovarian cancer risk is indicated by the increased incidence of these cancers among women with a family history (National Comprehensive Cancer Network). The mechanism of breast and ovarian carcinogenesis is still not well understood (Yoneda et al., 2012) . It has been reported that several potential genes (with low, medium and high penetrance) and combining with environmental factors may be important in the development of these malignancies (Xu et al., 2014; Yoneda et al., 2012) .
The X-Ray Repair Cross-Complementing Group 2 (XRCC2) gene encodes a member of the Rad51 family of related proteins that maintains chromosome stability by participating in homologous recombination and repairs DNA damage. The XRCC2 and XRCC3 are two of the members of RAD51-related proteins (Michalska et al., 2016; Sobhan et al., 2017) . The XRCC2 gene has roles in the homologous recombination repair (HRR) pathway of double-stranded DNA, which repairs chromosomal fragmentation, deletions and translocations (Kuschel et al., 2002) . A significant number of single nucleotide polymorphisms (SNPs) have been identified in the XRCC2 gene such as rs3218536 (Arg188His), rs718282, rs3218384, rs3218550, rs3218408, rs2040639 and rs3218499 (Xu et al., 2014; Sarwar et al., 2016) . Of these SNPs, XRCC2 rs3218536 polymorphism is caused by A to G transition in exon 3 and results in Arginine (Arg) in substitution of Histidine (His) at codon 188 of the protein. However, it is thought that the XRCC2 rs3218536 polymorphism associated with a lowered risk for breast cancer and epithelial ovarian cancer. To date, several studies have been conducted to evaluate the association of XRCC2 rs3218536 polymorphism with breast and ovarian cancer. However, the conclusions have been conflicting. Therefore, we performed the current meta-analysis to clarify the association between XRCC2 rs3218536 polymorphism with risk of breast and ovarian cancer.
Materials and Methods

Literature and Search Strategy
We have conducted a systematic literature search using the PubMed, Gene, Google scholar, Web of Science and EMBASE database to find studies assessing the association between XRCC2 rs3218536 polymorphism and two breast and ovarian cancer up to January 20, 2017. We sought publication with the following key words: ''breast cancer'', ''ovarian cancer'', ''X-Ray Repair Cross Complementing 2'', ''DNA repair protein XRCC2'', ''XRCC2'', ''rs3218536'', "single nucleotide polymorphism", "polymorphism", "SNP", "mutation", and "variation". In addition, we have identified related studies by hand screening of included studies. The search was limited to human studies were published only in English language.
Inclusion Criteria and Data Extraction
The studies included in the current meta-analysis meet the following criteria: (1) evaluates the associations between XRCC2 rs3218536 polymorphism and breast and ovarian cancer risk; (2) used case-control or prospective cohort design; and (3) containing at least genotype frequencies for estimating an odds ratio (OR) with 95% confidence interval (95% CI). In addition, the exclusion criteria were as the follows: (1) not conducted on human subjects, (2) not breast and ovarian cancer research (3) only included patients or healthy subjects, (4) duplicate of previous publications (completely or partially), and (5) above all, have not sufficient data about frequency of genotypes.
Data extraction
For each study, we have extracted carefully (two authors independently) the following data: First author, publication year, country of origin, ethnicity, number of cases and controls, and Hardy-Weinberg Equilibrium (HWE). Any disagreements were discussed and resolved through consensus with a third investigator. In this meta-analysis the subject's (cases and controls) ethnicities were categorized as Caucasian, Asian, or African.
Statistical analysis
The strength of association was assessed by calculating the odds ratios and 95% confidence intervals and the Z-test was used to evaluate statistical significance with P-values less than 0.01 considered as statistically significant. Pooled ORs were estimated for five genetic contrast including allele (A vs. G), heterozygote (AG vs. GG), homozygote (AA vs. GG), dominant (AA+AG vs. GG) and recessive (AA vs. AG+GG) contrasts. In the current meta-analysis, the heterogeneity between studies was calculated by X2-based Q test and I2. The heterogeneity were considered significant when p value was less than 0.05 for the Q test or I2>25% in I2 statistics. Moreover, a random effects model using the DerSimonian was utilized to calculate the OR and 95% CI for comparisons with moderate to high heterogeneity (P-value > 0.1 and I2 > 25%) (DerSimonian et al., 1986) . Otherwise, a fixed-effects model using the Mantel-Haenszel method was used. Sensitivity analysis was performed by sequential omission of individual studies (leave-one-out analysis) for various genetic models in the overall population and for subgroup analysis by ethnicity and HWE status. We have evaluated publication bias graphically using the Begg's funnel plot and statistically using the method of Egger's linear regression test (Egger et al., 1997) ; P<0.05 indicated that the result was statistically significant. We have used comprehensive meta-analysis (CMA) V2.0 software (Biostat, USA) to perform all the statistical analyses. Two-sided P values < 0.05 were considered statistically significant.
Results
Characteristics of the included studies
Based on the established search criteria, articles were retrieved for the association of XRCC2 rs3218536 polymorphism with breast and ovarian cancer susceptibility. Twenty publications (26 studies) met the inclusion criteria, the characteristics of which are showed in Table 1 and 2. Of these 20 publications, 16 publications (17 studies) with 5694 cases and 6450 controls evaluate the association of XRCC2 rs3218536 polymorphism with breast cancer risk. Two out of the 17 studies were published in Asians (Ding et al., 2014; Qureshi et al., 2014) and the others were in Caucasians (Rafii et al., 2002; Kuschel et al., 2002; Han et al., 2004; Webb et al., 2005; Millikan et al., 2005; Garcia-Closas et al., 2006; Brooks et al., 2008; Loizidou et al., 2008; Pooley et al., 2008; Silva et al., 2010; Jakubowska et al., 2010; Makowska et al., 2012; Smolarz et al., 2014; Shadrina et al., 2014) . There were 15 studies of Caucasian descendants (USA, UK, Poland, Australia, Portugal, Russia and Cyprus) and 2 studies of East Asian descendants communities (China and Pakistan). In addition, of these 20 publications, 5 publications (9 case-control studies) with 4464 cases and 6353 controls for association between XRCC2 rs3218536 polymorphism and ovarian cancer. The populations came from different 95% CI = 0.873-0.987, p=0.018) in the overall population ( Figure 2E ). Considering the limited number of qualified studies in the Asian and other descendent population, the stratified analyses was only presented for Caucasians.
In the subgroup analyses of ethnicity, the meta-analysis results indicated a strong association between the XRCC2 rs3218536 polymorphism and breast cancer susceptibility among Caucasians only under the heterozygote contrast (AG vs. GG: OR = 0.920, 95% CI = 0.861-0.980, p=0.009). Additionally, significant associations between the XRCC2 rs3218536 polymorphism and breast cancer under the recessive contrast (AG vs. GG: OR = 1.635, 95% CI = 1.109-2.413, p=0.013) was found according to the HWE.
Association of XRCC2 rs3218536 polymorphism and ovarian cancer
The meta-analysis of a possible association between the XRCC2 rs3218536 polymorphism and risk of ovarian countries, including UK, Denmark, USA, Australia, Egypt and Poland. There were 8 studies (Auranen et al., 2005; Webb et al., 2005; Beesley et al., 2007; Michalska et al., 2016) of Caucasian descendants and 1 study (Mohamed et al., 2013) of African descendant. Genotype distributions in the controls of two studies for breast cancer (Loizidou et al., 2008; Silva et al., 2010) and two studies for ovarian cancer (Mohamed et al., 2013; Michalska et al., 2016) were not in agreement with HWE (p < 0.05).
Meta-analysis Association of XRCC2 rs3218536 polymorphism and breast cancer
The meta-analysis of a possible association between XRCC2 rs3218536 polymorphism and breast cancer is summarized in Tables 3. Based on the total study population, a strong association was found between of XRCC2 rs3218536 polymorphism and breast cancer under the heterozygote contrast (AG vs. GG: OR = 0.929, Figure 2a ).
Test of heterogeneity
For XRCC2 rs3218536 polymorphism and breast cancer, when the data pooled a significant heterogeneity observed in allele (I 2 =79.49%, P h =<0.001), homozygote (I 2 =66.50%, P h =0.042), dominant (I 2 =86.39%, P h =<0.001) and recessive (I 2 =78.06%, P h =<0.001) contrasts (Table  3) . After subjects stratified by ethnicity and HWE status, the heterogeneity not disappeared obviously (Table  3) . For XRCC2 rs3218536 polymorphism and ovarian cancer, when the data pooled a significant heterogeneity observed in allele (I 2 =97.33%, Ph=<0.001), heterozygote (I 2 =82.27%, P h =<0.001), homozygote (I 2 =82.73%, P h =<0.001), dominant (I 2 =80.96%, P h =<0.001) and recessive (I 2 =92.22%, P h =<0.001) contrasts (Table 4 ). After subjects stratified by ethnicity and HWE status, the heterogeneity not disappeared obviously Caucasian. However, by HWE status the heterogeneity disappeared obviously in heterozygote (I 2 =12.14%, P h =0.337), homozygote (I 2 =0.00%, P h =0.629) and recessive (I 2 =10.04%, P h =0.352) contrasts (Table 4) .
Publication bias
Both Begg's funnel plot and Egger's test were performed to assess the publication bias of literatures. The shapes of the funnel plots revealed no obvious asymmetry for association of XRCC2 rs3218536 polymorphism with breast cancer in the overall analyses (Figure 2A) . However, the results of Egger's regression test provided sufficient evidence for publication bias in dominant contrast (P Begg's =0.108, P Eggers =0.016), suggesting that there was obvious publication bias in the genetic contrast. In addition, the publication bias has seen in the meta-analysis XRCC2 rs3218536 polymorphism in Caucasians (dominant contrast: P Begg's =0.108, P Eggers =0.016) and by HWE status (allele contrast: P Begg's =0.165, P Eggers =0.033; dominant contrast: P Begg's =0.047, P Eggers =0.009). Moreover, the results of Egger's regression test provided evidence of publication bias for association of XRCC2 rs3218536 polymorphism with ovarian cancer in allele (P Begg's =1.000, P Eggers =0.033), homozygote (P Begg's =0.465, P Eggers =0.002) and recessive contrasts (P Begg's =0.916, P Eggers =0.002) in overall analysis. In addition, the publication bias has seen in the meta-analysis XRCC2 rs3218536 polymorphism and ovarian cancer in Caucasians (allele: P Begg's =1.000, P Eggers =0.045; homozygote: P Begg's =0.901, P Eggers =0.002 and recessive contrasts: P Begg's =0.901, P Eggers =0.001).
Discussion
In this meta-analysis, we have evaluated the associations of XRCC2 rs3218536 polymorphism with breast and ovarian cancer susceptibility. To the best knowledge, our data suggested a significant association between the XRCC2 rs3218536 polymorphism and increased risk for breast cancer under heterozygote contrast. Additionally, the dominant contrast for the XRCC2 rs3218536 polymorphism indicated increased risk for OC.
Several meta-analyses have estimated the association between XRCC2 rs3218536 polymorphism and breast cancer risk (Yu et al., 2010; He et al., 2014; Kong et al., 2015; Zhang et al., 2016) . He et al., (2014) Many factors may contribute to the strong heterogeneity among overall analysis (Mehdinejad et al., 2017; Jafari Nedooshan et al., 2017) . In the meta-analysis of XRCC2 rs3218536 polymorphism and breast cancer, the heterogeneity between studies was not significantly reduced in the subgroup analysis by the ethnicity and HWE, which indicating that the effect of XRCC2 rs3218536 in development breast cancer may not be modified by ethnicity and HWE. However, the heterogeneity between studies in the meta-analysis of XRCC2 rs3218536 polymorphism and ovarian cancer was significantly reduced by HWE status.
To the best knowledge, current meta-analysis is by far the most comprehensive and convicting on the association of the XRCC2 rs3218536 polymorphism with breast and ovarian cancer susceptibility to date. This meta-analysis has two strengths compared with previous meta-analysis as follow; first, in this meta-analysis, relatively all eligible studies with large sample sizes were included, which would decrease the risk of random error. Second, the quality of eligible publications included in meta-analysis was more satisfactory and met mostly the inclusion criteria. However, some limitations should be taken into consideration when explaining the results as follow: first, most of the studies included in the meta-analysis were performed in the Caucasian population, the limited number was from Asians (only two publications) and there was no relevant study from Africans. However, most subjects were from Caucasian, but limited to the UK, Poland and USA.
Thus, to obtain more precise meta-analysis of XRCC2 rs3218536 polymorphism on breast and ovarian cancer susceptibility, additional studies with larger sample size and involving different ethnicities especially Asians and African are required. Second, because we have included only relevant published articles and written in English language in the meta-analysis, publication bias may have occurred, even though it was not found by making use of statistical tests. Third, the overall outcomes were based on individual unadjusted ORs without adjustment for other risk factors such as age, histological subtypes, clinical stages, menstrual status, environmental and other confounding lifestyle factors. Finally, this meta-analysis could not address the gene-gene and gene-environmental interactions in the association between XRCC2 rs3218536 polymorphism and risk of breast and ovarian cancer. Therefore, future studies that include detailed information on exposures to environmental factors to assess the possible gene-gene and gene-environment interactions in the association between XRCC2 rs3218536 polymorphism and risk of breast and ovarian cancer are required.
In summary, this systematic review and meta-analysis shows that the XRCC2 rs3218536 polymorphism was associated with breast and ovarian cancer susceptibility in overall population and Caucasians. According to the limitations listed above, Asian and African descendent studies should be similarly performed.
